The Pre-Clinical Science Behind the CJC-1295 (No DAC) and Ipamorelin Research Blend
In modern endocrinology and molecular peptide research, single-target secretagogues often reach pharmacological plateaus. To overcome these limits, investigators frequently study dual-agonist combinations. Among the most widely documented pairs is the CJC-1295 (No DAC) and Ipamorelin peptide blend. By co-targeting two distinct receptor pathways on anterior pituitary somatotrophs, this blend allows researchers to examine synergistic growth […]